acr-2316
·Code: ACR-2316
acr-2316: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | Phase 2 |
FDA Decisions
FDA_MeetingFDA cleared the Investigational New Drug application for ACR-2316; initial clinical sites activated and first-in-human Phase 1 dosing expected in Q4 2024.(ACRV)
Frequently asked questions
Who is developing acr-2316?
acr-2316 is being developed by Acrivon Therapeutics, Inc..
What is acr-2316's latest FDA decision?
The most recent tracked FDA decision for acr-2316 is FDA_Meeting for FDA cleared the Investigational New Drug application for ACR-2316; initial clinical sites activated and first-in-human Phase 1 dosing expected in Q4 2024., dated September 14, 2024.
Get deeper analysis on acr-2316
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis